Loading
Life sciences · Review
Nutrients · October 1, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Review.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background: Obesity is associated with impaired skeletal muscle health and sarcopenic obesity. GLP-1-based pharmacotherapies induce weight loss, but accompanying reductions in fat-free or lean mass raise concerns about skeletal muscle loss. Conversely, reductions in adiposity, inflammation, insulin resistance, and intramuscular fat may be beneficial. Objective: This narrative review evaluated the effects of GLP-1-based pharmacotherapies on body composition, muscle quantity, composition and function, and their potential role in sarcopenia. Methods: PubMed and Google Scholar were searched for clinical and experimental studies published primarily between 2016 and 2026. Results: Preclinical studies identified potentially protective mechanisms, including improved insulin sensitivity, reduced inflammation, and modulation of mitochondrial function and protein turnover, but some also indicated muscle loss or proteolysis. Clinical studies reported greater reductions in fat mass than in fat-free or lean mass, neither of which represents skeletal muscle exclusively. Direct muscle and functional outcomes were assessed in few studies and yielded mixed results. Incident sarcopenia was rarely evaluated. Conclusions: GLP-1-based pharmacotherapies may influence sarcopenia risk through competing pathways. Metabolic improvements may support muscle health, whereas energy restriction, inadequate protein intake, gastrointestinal adverse effects, and lean tissue loss may increase vulnerability. Current evidence is insufficient to determine their net effect on sarcopenia risk.